Several lines of evidence from preclinical studies have demonstrated the crucial roles of SGLT2 inhibitors in combating the “multiple-hit” pathogenesis of NAFLD, especially in reducing oxidative stress and inflammation. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.